Comparison of the Efficacy of Two Vaginal Progesterone Formulations, Crinone 8% Gel and Utrogestan Capsules, Used for Luteal Support in Blastocyst Stage Embryo Transfers  by Wang, Li-Jung et al.
Taiwan J Obstet Gynecol • December 2009 • Vol 48 • No 4 375
■ ORIGINAL ARTICLE ■
Introduction
Stimulated in vitro fertilization (IVF) cycles are associated
with defective luteal phases in almost all patients [1],
particularly with the induction of high estradiol levels
[2,3]. The use of a long protocol with a gonadotropin-
releasing hormone agonist during assisted reproductive
technology (ART) treatment is commonly used to pre-
vent the premature luteinizing hormone surge and to
control the number and growth of follicles. The long
protocol suppresses the pituitary gland and blocks the
secretion of luteinizing hormone for at least 10 days
following the last dose of gonadotropin-releasing hor-
mone [4]. It is, therefore, not surprising that the luteal
phase becomes dysfunctional and an inadequate
amount of progesterone is produced in ART cycles
stimulated after downregulation with gonadotropin-
releasing hormone agonists. In addition to a low
luteinizing hormone serum concentration during the
luteal phase, supraphysiologic steroid levels during the
early and mid-luteal phases of stimulated cycles may
advance endometrial development and inhibit embryo
implantation [5,6].
The benefit of luteal phase support (LPS) in 
downregulated cycles has been verified in prospective 
randomized trials [7–9]. However, a standard protocol
for LPS has not been established (i.e. optimal formula,
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dose, route, timing, and duration). Both human chori-
onic gonadotropin (hCG) and progesterone have been
used for LPS. Progesterone is used more frequently
than hCG because of a lower risk of ovarian hyperstimu-
lation syndrome [10].
Progesterone can be administrated orally, vaginally
or intramuscularly. Orally administered progesterone
is rapidly metabolized in the gastrointestinal tract and
has been shown to be inferior to intramuscular and
vaginal routes, leading to a poorer outcome of IVF. Com-
parisons of vaginal and intramuscular progesterone have
yielded conflicting results. Nevertheless, the vaginal
route may provide a valuable route for drug delivery
because of the postulated first uterine pass effect and
the avoidance of the discomfort and side effects of an
intramuscular injection [11].
Blastocyst transfer (BT) is a valuable tool in the
hands of practitioners of IVF, and has been accepted
by many IVF programs throughout the world. BT has
facilitated the natural selection of good-quality embryos
that are reported to generate high implantation rates,
while lowering multiple gestation rates following IVF
[12]. The issue of LPS in BT cycles (higher stimulated
estradiol levels than in cleavage stage cycles) has been
less thoroughly assessed.
The purpose of this study was to compare the 
efficacy of two vaginal progesterone preparations
(Utrogestan capsules and Crinone 8% gel), which are
used for LPS during IVF in BT.
Materials and Methods
Patients
Data were collected from consecutive infertile couples
who underwent ART and transcervical fresh BT between
January 2004 and December 2007. All patients were
unselected and were included without regard to age,
sperm parameters or infertility criteria. During the study
period, 547 patients underwent BT using IVF or intra-
cytoplasmic sperm injection (ICSI) with vaginal luteal
support in our hospital. A total of 299 patients received
luteal progesterone support with Crinone 8% gel during
BT cycles and 248 patients received Utrogestan vaginal
capsules. Eighteen patients receiving Utrogestan vaginal
capsules, who experienced difficulties in BT or donor
cycles, or who had rare treatment indications, were ex-
cluded from this study. For outcome comparison and to
avoid selection bias, a case-control design was used to
recruit 230 patients with Crinone 8%-supported cycles,
based on the demographic characteristics of the 230 pa-
tients with Utrogestan-supported cycles. Demographic
characteristics were selected in the following decreasing
order of priority: (1) age, (2) embryos transferred and
number of top-quality embryos transferred, (3) estra-
diol and progesterone level on hCG day, (4) number of
oocytes retrieved, (5) follicle-stimulating hormone (FSH)
treatment period and protocol, and (6) etiology of infer-
tility. We ideally aimed to control for all six variables;
but if this was not possible, we tried to control for at
least the first four variables in each case-control pair.
This study was approved by the ethics committee
of Chang Gung Memorial Hospital. Approval from the
institutional review board was obtained for analysis of
this series.
Controlled ovarian hyperstimulation and 
oocyte retrieval
The protocol for controlled ovarian hyperstimulation
followed the standard downregulation regimen, as
previously reported [13,14]. Briefly, all women received
either the long or short protocol for pituitary down-
regulation with leuprolide acetate (Lupron; Takeda,
Tokyo, Japan), depending on ovarian reserve, as assessed
by the patient’s age, baseline serum FSH concentration
or previous response to ovarian stimulation. Exogenous
FSH was administered at an initial dose of 150–300 IU,
with further doses given according to the individual’s
ovarian response, as assessed by serum estradiol level
determination and sonographic follicular growth mon-
itoring. When the lead follicle reached 16–18 mm in
diameter, leuprolide acetate and FSH were discontinued
and hCG was administered. Oocyte retrieval was per-
formed by transvaginal ultrasound-guided follicle
aspiration 36–38 hours after hCG administration.
Embryo culture, embryo grading, and embryo transfer
A single team of embryologists coordinated all proce-
dures, thus ensuring that both the culture protocols
and the embryo assessment were standardized, as des-
cribed previously [15]. Any zygotes with two pronuclei
were cultured until the day of embryo transfer. G1 me-
dium (Scandinavian IVF Science, Kungsbacka, Sweden)
was used for culturing embryos on days 1–3. G2 medium
(Scandinavian IVF Science, Kungsbacka, Sweden) was
used for culturing embryos from days 3–5 or 6. In our
program, we have routinely offered BT of embryos to
patients with more than three eight-cell embryos on 
day 3. We strictly defined “top-quality” embryos as
follows: (1) embryos that formed full blastocysts (full
blastocysts onward, the development of an inner cell
mass with many tightly packed cells, and with trophec-
toderm and many cells forming a cohesive epithelium);
(2) embryos derived from Z1 zygotes (zygotes with
equal numbers of nucleoli aligned at the pronuclear
junction; the absolute number was not counted, but
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was between 3 and 7); and (3) embryos that were grade
1 (eight cells, blastomeres of equal size, and no cytoplas-
mic fragments) and had day 3 embryo morphology
[14]. All embryo transfers were performed gently using
a Labotect catheter (Labotect, Göttingen, Germany).
Luteal support
The study population was divided into two groups.
One group received Crinone 8% gel (90 mg daily; Fleet
Laboratories Ltd., Watford, UK), and one group received
Utrogestan vaginal capsules (200 mg four times daily;
Piette International Laboratories, Drogenbos, Belgium).
Luteal phase supplementation of micronized proges-
terone was begun on the day of oocyte retrieval and
continued until the day pregnancy was confirmed by
detection of hCG in the urine. These two formulas
were available from the hospital during the study period.
However, the choice of a particular formula depended
on the affordability to the patient and the convenience
of application. The day after BT, we offered a single
booster dose of 250 μg recombinant hCG (Ovidrel;
Industria Farmaceutica Serono S.p.A, Rome, Italy).
Determination of pregnancy status
Pregnancy was confirmed by detecting hCG in the
urine 2 weeks after transfer. Clinical pregnancy was
determined by identifying a gestational sac at 7 weeks’
gestation by means of transvaginal ultrasonography.
Statistical analysis
The SigmaStat statistical package (Jandel Corporation,
San Rafael, CA, USA) was used for data analysis.
Continuous data were summarized as the means ±
standard deviations. Unpaired Student’s t tests or Mann-
Whitney rank sum tests were used for comparisons
between means, and Fisher’s exact tests were used to
compare proportions. All p values were two-sided, and
a p value of <0.05 was considered statistically significant.
Results
Demographic data for 230 patients receiving luteal
progesterone support with Crinone 8% gel during BT
cycles and 230 patients receiving Utrogestan vaginal
capsules are shown in Table 1. No significant differ-
ences were noted between the groups with regard to
patient age, body mass index, days and dosage of
stimulation, indication for treatment, endometrial thick-
ness on day of hCG, and estradiol and progesterone
levels on the hCG day.
There were no significant differences between 
the groups in terms of number of oocytes retrieved,
fertilization rate, number of embryos transferred or
mean number of top-quality embryos transferred. The
clinical pregnancy rates per transfer (58.7% vs. 44.3%)
and implantation rates (32.04% vs. 23.89%) were sig-
nificantly higher in the Crinone group, compared with
the Utrogestan group. The pregnancy loss rates were
similar in the two groups (Table 2).
Discussion
In general, LPS is more important in high-responding
cycles with advanced endometrial histology [16–18]. 
It increases uterine contractions at the time of embryo
transfer [19]. In an earlier study, we showed that in
day-3 cleavage stage embryo transfers, usually with an
inferior ovarian response, LPS with Crinone 8% gel or
micronized progesterone had comparable effects (data
not shown). The primary objective of the current study
was to compare the efficacy of two vaginal formulations
of progesterone (Crinone 8% and Utrogestan capsules)
used for LPS in ART cycles, especially in a BT program.
The demographics and ART-specific characteristics
of the patients were similar in the two groups. The
results showed that Crinone 8% gel resulted in higher
implantation (32.04% vs. 23.89%) and clinical preg-
nancy rates (58.7% vs. 44.3%) than Utrogestan capsules.
The pregnancy loss rates were not significantly differ-
ent between the two groups. These findings suggest that
for similar numbers of BT, LPS with Crinone 8% gel is
more effective than with Utrogestan capsules in high
responder cycles.
LPS with progesterone has become a standard
treatment in IVF/ICSI cycles to overcome the luteal phase
defect and to improve the result of ART. No significant
differences were found between progesterone and hCG
in terms of pregnancy or miscarriage rates, but the risk
of ovarian hyperstimulation syndrome was more than
twofold higher with treatments involving hCG than
with progesterone alone [20]. Various routes of prog-
esterone administration have been developed and
tested. There is increasing evidence in the literature to
suggest that vaginal administration of progesterone
could be superior to other routes, mainly because of
the postulated first uterine pass effect, which results in
better local progesterone bioavailability in the uterus
[11]. Patients may also feel more comfortable with the
vaginal route, which avoids the painful injection of
intramuscular progesterone and its side effects [10].
No significant differences in pregnancy rates have
been observed between vaginal progesterone gel and
other types of vaginal progesterone [20]. To date, few
studies have compared vaginal gel (Crinone 8%) and
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vaginal progesterone capsules (Utrogestan) used for
LPS. Kleinstein et al [21] reported that the use of vaginal
progesterone capsules (Utrogest 200 mg, three times per
day) compared with vaginal gel (Crinone 8%, twice per
day) for LPS in ART cycles resulted in similar out-
comes. Geber et al [22] concluded that there was no
statistically significant difference in pregnancy rates
between vaginal capsules of 200 mg of micronized
progesterone (Utrogestan, three times daily) and
micronized progesterone gel (Crinone 8%, once daily),
although the pregnancy rate was higher in those
patients receiving progesterone gel, compared with
capsules (44.26% and 36.06%, respectively). Simunic
et al [23] also reported similar efficacies of the two
vaginal progesterone formulations, but the tolerability
and acceptability of Crinone 8% gel were superior.
The present study showed that the vaginal formula-
tion of Crinone 8% gel (90 mg, once daily) resulted in
higher implantation and clinical pregnancy rates when
used for LPS during IVF with BT. Although the optimal
length of treatment is unclear, our experience suggests
that it is sufficient to support the luteal phase until the
day of a positive hCG test, as recommended in the recent
literature [1].
Admittedly, the results of this retrospective case-
control study do not provide any definitive conclusions.
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Table 1. Demographic and specific treatment characteristics of patients*
Patient group
Crinone (n = 230) Utrogestan (n = 230)
p
Patient age (yr) 32.78 ± 3.84 33.05 ± 4.78 0.505
Body mass index (kg/m2) 21.54 ± 3.07 21.92 ± 3.62 0.098
Duration of infertility (yr) 4.09 ± 2.79 3.98 ± 2.91 0.682
Indication for treatment
Tubal factor 64 52 0.198
Male factor 80 78 0.845
Endometriosis 20 19 0.867
Ovulatory factor 21 19 0.741
Unexplained 33 47 0.085
Other 12 15 0.553
Days of FSH treatment 9.07 ± 1.50 8.82 ± 1.89 0.119
Ampoules of 75 IU FSH 32.07 ± 11.85 30.29 ± 10.61 0.091
Endometrial thickness on hCG day (cm) 1.34 ± 0.30 1.32 ± 0.34 0.626
Estradiol (pg/mL) on hCG day 2,313.31 ± 1,241.30 2,201.74 ± 1,212.26 0.34
Progesterone (ng/mL) on hCG day 1.50 ± 0.89 1.59 ± 1.49 0.436
*Data are presented as mean ± standard deviation or n. FSH = follicle-stimulating hormone; hCG = human chorionic gonadotropin. 
Table 2. Results in study groups
Patient group
Crinone (n = 230) Utrogestan (n = 230)
p
No. of oocytes retrieved, mean ± SD 8.43 ± 2.85 7.93 ± 2.85 0.086
Normal fertilization rate (%) 83.51 81.96 0.211
Mode of fertilization
Conventional IVF, n 165 166 0.917
ICSI, n 65 64 0.917
No. of embryos transferred, mean ± SD 2.47 ± 0.57 2.44 ± 0.68 0.603
No. of top-quality embryos transferred, 1.59 ± 0.69 1.66 ± 0.67 0.272
mean ± SD
Clinical pregnancy rate/transfer cycle, n (%) 135/230 (58.7) 102/230 (44.3) 0.001
Implantation rate, n (%) 182/568 (32.04) 134/561 (23.89) 0.002
Abortion rate (%) 5.19 8.82 0.269
SD = standard deviation; IVF = in vitro fertilization; ICSI = intracytoplasmic sperm injection.
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However, all participants underwent BT and had simi-
lar numbers of top-quality embryos to transfer, unlike
in other associated studies. In our previous top-quality
embryo transfer study [14], we identified a subpopula-
tion of blastocysts (top-quality blastocysts) with high
implantation potential. Nevertheless, the results of the
present study demonstrated superiority of Crinone 8%
gel over Utrogestan capsules for LPS in BT cycles using
equal numbers of top-quality embryos.
In conclusion, LPS with Crinone 8% vaginal gel
(90 mg daily) resulted in better clinical pregnancy and
implantation rates than Utrogestan vaginal capsules
(200 mg, four times daily) in IVF/ICSI–BT cycles. A well-
designed, adequately powered, multicenter, prospective,
randomized, controlled trial should be undertaken to
verify these findings.
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